Clinical trial
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in…
NCT00326768 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00326768 |
|---|---|
| Title | Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension |
| Official title | An Open-Label, Long-term (52-week), Safety Trial of the Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg and Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg in Patients With Essential Hypertension - Efficacy and Safety Evaluation |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Telmisartan 40 mg/HCTZ 12.5 mg, Telmisartan 40 mg, Telmisartan 80 mg/HCTZ 12.5 mg |
| Enrollment | 184 |
| Start date | May 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | May 17, 2006 |
| Last update posted | Dec 28, 2017 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: